Advanced search
Publication Cover
OncoImmunology Volume 9, 2020 - Issue 1
Submit an article Journal homepage
2,435
Views
28
CrossRef citations to date
0
Altmetric
Editorial

Lurbinectedin: an FDA-approved inducer of immunogenic cell death for the treatment of small-cell lung cancer

Oliver Keppa Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM UMR1138, Centre de Recherche des Cordeliers, Paris, France;b Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, FranceORCID Iconhttps://orcid.org/0000-0002-6081-9558
ORCID Icon,
Laurence Zitvogelc Gustave Roussy Cancer Center, Inserm U1015, Villejuif, France;d Gustave Roussy Cancer Center, Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 1428, Villejuif, France;e Faculty of Medicine, Université Paris Saclay, Le Kremlin-Bicêtre, France;f Chinese Academy of Medical Sciences, Suzhou Institute for Systems Medicine, Suzhou, ChinaORCID Iconhttps://orcid.org/0000-0003-1596-0998
ORCID Icon &
Guido Kroemera Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM UMR1138, Centre de Recherche des Cordeliers, Paris, France;b Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Villejuif, France;f Chinese Academy of Medical Sciences, Suzhou Institute for Systems Medicine, Suzhou, China;g Pôle De Biologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France;;h Karolinska Institutet, Department of Women’s and Children’s Health, Karolinska University Hospital, Stockholm, SwedenCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-9334-4405
ORCID Icon
Article: 1795995 | Received 09 Jul 2020, Accepted 10 Jul 2020, Published online: 21 Jul 2020

References

  • Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell. 2015;28:690–3. doi:10.1016/j.ccell.2015.10.012.
  • Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, Coukos G, Demaria S, Deutsch E, et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. J Immunother Cancer. 2020;8:e000337. doi:10.1136/jitc-2019-000337.
  • Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science. 2011;334:1573–1577. doi:10.1126/science.1208347.
  • Vacchelli E, Ma Y, Baracco EE, Sistigu A, Enot DP, Pietrocola F, Yang H, Adjemian S, Chaba K, Semeraro M, et al. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science. 2015;350:972–978. doi:10.1126/science.aad0779.
  • Yang H, Ma Y, Chen G, Zhou H, Yamazaki T, Klein C, Pietrocola F, Vacchelli E, Souquere S, Sauvat A, et al. Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy. Oncoimmunology. 2016;5:e1149673. doi:10.1080/2162402X.2016.1149673.
  • Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, Schmitt E, Hamai A, Hervas-Stubbs S, Obeid M, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med. 2005;202:1691–1701. doi:10.1084/jem.20050915.
  • Bezu L, Sauvat A, Humeau J, Gomes-da-Silva LC, Iribarren K, Forveille S, Garcia P, Zhao L, Liu P, Zitvogel L, et al. eIF2alpha phosphorylation is pathognomonic for immunogenic cell death. Cell Death Differ. 2018;25:1375–1393. doi:10.1038/s41418-017-0044-9.
  • Humeau J, Sauvat A, Cerrato G, Xie W, Loos F, Iannantuoni F, Bezu L, Lévesque S, Paillet J, Pol J, et al. Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress. EMBO Mol Med. 2020;12:e11622. doi:10.15252/emmm.201911622.
  • Galluzzi L, Humeau J, Buque A, Zitvogel L, Kroemer G. Immunostimulation by chemotherapy in the era of immune checkpoint blockers. Nat Rev Clin Oncol. 2020;17:49-64. doi:10.1038/s41571-019-0272-7
  • Santamaria Nunez G, Robles CMG, Giraudon C, Martinez-Leal JF, Compe E, Coin F, Aviles P, Galmarini CM, Egly J-M. Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase ii and the formation of DNA breaks in cancer cells. Mol Cancer Ther. 2016;15:2399–2412. doi:10.1158/1535-7163.MCT-16-0172.
  • Xie W, Forveille S, Iribarren K, Sauvat A, Senovilla L, Wang Y, Humeau J, Perez-Lanzon M, Zhou H, Martínez-Leal JF. Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity. Oncoimmunology. 2019;8:e1656502. doi:10.1080/2162402X.2019.1656502.
  • Saltos A, Antonia S. Breaking the impasse: advances in treatment of small cell lung cancer. Clin Chest Med. 2020;41:269–280. doi:10.1016/j.ccm.2020.02.011.
  • Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA, Peters S, Ponce S, Fernández C, Alfaro V, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020;21:645–654. doi:10.1016/S1470-2045(20)30068-1.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.